Revolution Medicines Inc(RVMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -8.81 | Insider Own | 9.93% | Shs Outstand | 214.2M | Perf Week | 5.07% |
| Market Cap | 40.08B | Forward P/E | - | EPS next Y | 38.96% | Insider Trans | -2.47% | Shs Float | 193.0M | Perf Month | -6.44% |
| Enterprise Value | 37.33B | PEG | - | EPS next Q | -2.35 | Inst Own | 93.83% | Short Float | 6.18% | Perf Quarter | -0.57% |
| Income | -1.77B | P/S | - | EPS this Y | -59.45% | Inst Trans | 6.54% | Short Ratio | 6.03 | Perf Half Y | 38.2% |
| Sales | 0.00B | P/B | 15.37 | EPS next 5Y | 26.05% | ROA | -52.37% | Short Interest | 11.93M | Perf YTD | 134.76% |
| Book/sh | 12.16 | P/C | 10.18 | EPS past 3/5Y | -24.48% -29.13% | ROE | -79.09% | 52W High | -16.64% ($224.31) | Perf Year | 249.91% |
| Cash/sh | 18.37 | P/FCF | - | Sales past 3/5Y | - | ROIC | -46.78% | 52W Low | 256.31% ($52.48) | Perf 3Y | 918.74% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -95.67% | Gross Margin | - | Volatility(W/M) | 5.3% 4.94% | Perf 5Y | 584.95% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 9.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.38 | EPS Q/Q | -132.54% | Profit Margin | - | RSI (14) | 43.87 | Recom | 1.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.38 | Sales Q/Q | - | SMA20 | -4.13% ($195.05) | Beta | 1.44 | Target Price | $258.84 |
| Payout | - | Debt/Eq | 0.46 | Earnings | 2026/8/5 | SMA50 | -7.24% ($201.58) | Rel Volume | 0.87 | Prev Close | $187.69 |
| Employees | 883 | LT Debt/Eq | 0.45 | EPS/Sales Surpr. | -49.81% -100% | SMA200 | 21.22% ($154.26) | Avg Volume(3M) | 1.98M | Price | $186.99 |
| IPO | 2020/2/13 | Option/Short | Yes/Yes | Trades | 18743 | Volume | 1,722,178 | Change | -0.37% |
🧪 Revolution Medicines is a US late-stage clinical oncology biotech company developing novel cancer drugs targeting RAS proteins. The company operates a clinical pipeline targeting a range of solid tumors — including pancreatic, colorectal, and lung cancers — built on its RAS(ON) inhibitor platform. Its lead candidate, daraxonrasib, has reported meaningful overall survival improvement results in a Phase 3 clinical trial.
Over the past 1 year, on the higher side
17% below its 1-year high.
Traded about as much as usual. That is 87% of its average volume.
RVMD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -59.5% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +585.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 93.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #5 of 595 in the industry
Based on market cap of $40B.
ARGX#4 Argen X SE ADR $55B PER 33.3 
RVMD#5 Revolution Medicines Inc $40B PER - 
ONC#6 BeOne Medicines Ltd ADR $39B PER 66.4 
RPRX#7 Royalty Pharma plc $37B PER 34.0 
ALNY#8 Alnylam Pharmaceuticals Inc $30B PER 37.8 
FAQ
What kind of company is RVMD?
RVMD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RVMD?
The market cap of RVMD is approximately $40.1B, ranking 382 within its sector.
What is the 52-week high and low for RVMD?
RVMD has recorded a 52-week high of $224.31 and a low of $52.48.
